Barriers to the effective treatment of sepsis: Antimicrobial agents, sepsis definitions, and host-directed therapies

Ngan H. Lyle, Olga M. Pena, John H. Boyd, Robert Hancock

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Sepsis is a complex clinical syndrome involving both infection and a deleterious host immune response. Antimicrobial agents are key elements of sepsis treatment, yet despite great strides in antimicrobial development in the last decades, sepsis continues to be associated with unacceptably high mortality (∼30%). This is the result, on one hand, of the rise of antimicrobial resistant organisms and, on the other hand, of the dearth of effective host-directed immune therapies. A major obstacle to the development of good host-directed therapies is the lack of understanding of the host immune response. The problem is exacerbated by poor nonspecific clinical definitions of disease. Poor definitions have had a profound impact on sepsis research, from epidemiologic studies to the failed clinical trials of host-directed therapies. Therefore, better definitions must be developed to enable advancement in the field.

LanguageEnglish
Pages101-114
Number of pages14
JournalAnnals of the New York Academy of Sciences
Volume1323
Issue number1
DOIs
Publication statusPublished - 1 Sep 2014

Keywords

  • Antimicrobial resistance
  • Host-directed therapies
  • Immunology
  • Sepsis
  • Sepsis definitions

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

@article{06dfb02f9872457c84949c6138ae71d6,
title = "Barriers to the effective treatment of sepsis: Antimicrobial agents, sepsis definitions, and host-directed therapies",
abstract = "Sepsis is a complex clinical syndrome involving both infection and a deleterious host immune response. Antimicrobial agents are key elements of sepsis treatment, yet despite great strides in antimicrobial development in the last decades, sepsis continues to be associated with unacceptably high mortality (∼30{\%}). This is the result, on one hand, of the rise of antimicrobial resistant organisms and, on the other hand, of the dearth of effective host-directed immune therapies. A major obstacle to the development of good host-directed therapies is the lack of understanding of the host immune response. The problem is exacerbated by poor nonspecific clinical definitions of disease. Poor definitions have had a profound impact on sepsis research, from epidemiologic studies to the failed clinical trials of host-directed therapies. Therefore, better definitions must be developed to enable advancement in the field.",
keywords = "Antimicrobial resistance, Host-directed therapies, Immunology, Sepsis, Sepsis definitions",
author = "Lyle, {Ngan H.} and Pena, {Olga M.} and Boyd, {John H.} and Robert Hancock",
year = "2014",
month = "9",
day = "1",
doi = "10.1111/nyas.12444",
language = "English",
volume = "1323",
pages = "101--114",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",
number = "1",

}

Barriers to the effective treatment of sepsis : Antimicrobial agents, sepsis definitions, and host-directed therapies. / Lyle, Ngan H.; Pena, Olga M.; Boyd, John H.; Hancock, Robert.

In: Annals of the New York Academy of Sciences, Vol. 1323, No. 1, 01.09.2014, p. 101-114.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Barriers to the effective treatment of sepsis

T2 - Annals of the New York Academy of Sciences

AU - Lyle, Ngan H.

AU - Pena, Olga M.

AU - Boyd, John H.

AU - Hancock, Robert

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Sepsis is a complex clinical syndrome involving both infection and a deleterious host immune response. Antimicrobial agents are key elements of sepsis treatment, yet despite great strides in antimicrobial development in the last decades, sepsis continues to be associated with unacceptably high mortality (∼30%). This is the result, on one hand, of the rise of antimicrobial resistant organisms and, on the other hand, of the dearth of effective host-directed immune therapies. A major obstacle to the development of good host-directed therapies is the lack of understanding of the host immune response. The problem is exacerbated by poor nonspecific clinical definitions of disease. Poor definitions have had a profound impact on sepsis research, from epidemiologic studies to the failed clinical trials of host-directed therapies. Therefore, better definitions must be developed to enable advancement in the field.

AB - Sepsis is a complex clinical syndrome involving both infection and a deleterious host immune response. Antimicrobial agents are key elements of sepsis treatment, yet despite great strides in antimicrobial development in the last decades, sepsis continues to be associated with unacceptably high mortality (∼30%). This is the result, on one hand, of the rise of antimicrobial resistant organisms and, on the other hand, of the dearth of effective host-directed immune therapies. A major obstacle to the development of good host-directed therapies is the lack of understanding of the host immune response. The problem is exacerbated by poor nonspecific clinical definitions of disease. Poor definitions have had a profound impact on sepsis research, from epidemiologic studies to the failed clinical trials of host-directed therapies. Therefore, better definitions must be developed to enable advancement in the field.

KW - Antimicrobial resistance

KW - Host-directed therapies

KW - Immunology

KW - Sepsis

KW - Sepsis definitions

UR - http://www.scopus.com/inward/record.url?scp=84907956165&partnerID=8YFLogxK

U2 - 10.1111/nyas.12444

DO - 10.1111/nyas.12444

M3 - Article

VL - 1323

SP - 101

EP - 114

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

IS - 1

ER -